Biotronik Rolls Out Biomonitor III Injectable Cardiac Monitor

The company says Biomonitor III documents suspected arrhythmias or unexplained syncope in patients who have experienced cardiac arrhythmias or who are at risk for cardiac arrhythmias.

Product Launch, Motivational Business Marketing Words Quotes Concept words lettering typography concept - Image
• Source: shutterstock.com

Biotronik SE & Co. KG says its new injectable cardiac monitor offers superior signal clarity and battery life to competing systems, which allows physicians to monitor patients for arrhythmias in less time per case and at lower cost.

Biomonitor III, which earned a 510(k) from the US Food and Drug Administration in July, automatically records arrhythmias, including atrial...

More from Cardiology

More from Device Area

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.

CDX Medical Technologies Secures $2.5M To Advance Smart ECMO Platform Toward FDA Approval

 
• By 

CDX is eying applications for its pump platform that go beyond ECMO. The company’s CEO says smart pumps that can be fine-tuned to patient volume and configuration are needed, and CDX is creating a scalable solution capable of supporting both acute and chronic lung care.

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.